For An Ultra-High-Priced Drug, Alnylam Brings A New Idea
Executive Summary
The company will launch Givlaari with a novel prevalence-based adjustment feature for payers, which will trigger higher rebates if the number of diagnosed patients is higher than expected.
You may also be interested in...
Alnylam Pursues Value Framework To Accelerate Givlaari Access In EU
Alnylam’s short-interfering RNA, Givlaari, has become the first treatment to be approved for preventing attacks of acute hepatic porphyria in the EU, and Alnylam wants to pursue a value-based agreement framework to accelerate patient and provider access.
EU: PRIME Success For Givlaari At CHMP
Interaction with the European Medicines Agency on Givlaari helped Alnylam prepare a more robust application package to demonstrate the medicine’s benefits and risks.
J.P. Morgan 2020: What To Watch For At The Industry’s Biggest Meeting
The J.P. Morgan Healthcare conference is being held a week later than usual, which only makes us more ready to hear what the industry's leaders have in store. Here's a preview of potential hot topics.